Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17714
Country/Region: South Sudan
Year: 2018
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USAID
Total Funding: $1,444,074 Additional Pipeline Funding: $239,270

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $53,323
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $32,856
Care: Pediatric Care and Support (PDCS) $85,318
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Prevention: HIV Testing and Counseling (HVCT) $319,938
Sexual Prevention: Other Sexual Prevention (HVOP) $37,761
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $339,846
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $533,235
Treatment: Pediatric Treatment (PDTX) $41,797
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative 2019 115
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative 2019 59
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive 2019 10
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative 2019 41
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative 2019 86
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive 2019 2
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative 2019 52
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive 2019 3
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative 2019 72
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive 2019 5
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative 2019 30
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative 2019 802
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive 2019 16
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative 2019 905
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive 2019 18
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative 2019 534
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive 2019 10
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative 2019 1,066
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive 2019 22
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative 2019 269
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive 2019 6
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative 2019 217
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive 2019 5
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative 2019 106
HTC_TST_DSD HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive 2019 2
HTC_TST_DSD HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative 2019 9
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative 2019 943
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive 2019 68
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative 2019 825
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive 2019 33
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative 2019 636
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive 2019 44
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative 2019 366
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive 2019 23
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative 2019 2,886
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive 2019 70
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative 2019 2,886
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive 2019 70
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative 2019 192
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive 2019 5
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative 2019 184
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive 2019 29
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative 2019 184
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive 2019 30
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative 2019 157
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive 2019 26
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative 2019 2,141
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive 2019 217
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative 2019 1,606
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive 2019 189
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative 2019 1,605
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive 2019 217
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative 2019 409
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive 2019 112
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive 2019 26
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive 2019 26
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 35,685
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 1-9, Negative 2019 43
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 1-9, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative 2019 36
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative 2019 16
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 114
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 110
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 753
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 16
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 165
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 157
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 157
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Community) Mobile Testing: <1, Negative 2019 2
HTC_TST_DSD Service Delivery Point (Facility) ANC: 1-9, Negative 2019 1
HTC_TST_DSD Service Delivery Point (Facility) ANC: 10-14, Negative 2019 962
HTC_TST_DSD Service Delivery Point (Facility) ANC: 10-14, Positive 2019 23
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Negative 2019 950
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Positive 2019 23
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Negative 2019 1,752
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Positive 2019 44
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Negative 2019 30
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 3
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 104
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 94
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 61
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 12
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 73
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 11
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 11
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 23
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 74
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 8
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 52
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 14
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 21
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 18
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 131
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 45
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 41
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 555
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 359
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 19
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 883
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 39
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 359
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 15
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 144
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 8
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 107
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 10
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Negative 2019 5
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Negative 2019 89
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Positive 2019 15
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 14
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 20
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 21
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 38
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 6
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 30
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 6
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 88
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 28
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 66
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 11
HTC_TST_DSD Service Delivery Point (Facility) TB: <1, Negative 2019 4
HTC_TST_DSD Service Delivery Point (Facility) TB: <1, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) VCT: 1-9, Negative 2019 350
HTC_TST_DSD Service Delivery Point (Facility) VCT: 1-9, Positive 2019 40
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 114
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 66
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 1,243
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 68
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 675
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 16
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 1,120
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 84
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 973
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 364
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 14
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 564
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 54
HTC_TST_DSD Service Delivery Point (Facility) VCT: <1, Negative 2019 52
HTC_TST_DSD Service Delivery Point (Facility) VCT: <1, Positive 2019 8
HTC_TST_DSD Service Delivery Point (Facility)Other PITC: <1, Negative 2019 8
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2019 145
PMTCT_ART_DSD New on ART 2019 230
PMTCT_ART_DSD Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 375
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 10,017
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2019 227
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2019 152
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 379
PMTCT_EID_DSD Sum of Infant Age disaggregates 2019 379
PMTCT_STAT_DSD By Age (Denominator): 10-14 2019 14
PMTCT_STAT_DSD By Age (Denominator): 20-24 2019 1,894
PMTCT_STAT_DSD By Age (Denominator): <15-19 2019 963
PMTCT_STAT_DSD By Age (Numerator): 10-14 2019 95
PMTCT_STAT_DSD By Age (Numerator): 15-19 2019 982
PMTCT_STAT_DSD By Age (Numerator): 20-24 2019 1,846
PMTCT_STAT_DSD By Number of known positives: 15-19 2019 8
PMTCT_STAT_DSD By Number of known positives: 20-24 2019 16
PMTCT_STAT_DSD By Number of new negative: 10-14 2019 95
PMTCT_STAT_DSD By Number of new negative: 15-19 2019 950
PMTCT_STAT_DSD By Number of new negative: 20-24 2019 1,735
PMTCT_STAT_DSD By Number of new positives: 15-19 2019 25
PMTCT_STAT_DSD By Number of new positives: 20-24 2019 93
PMTCT_STAT_DSD Number of new ANC and L&D clients 2019 10,579
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 10,017
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 25-29, Female 2019 4,017
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 30-34, Female 2019 3,163
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 35-39, Female 2019 528
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 25-29, Female 2019 5,002
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 30-34, Female 2019 2,084
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 35-39, Female 2019 8
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive 2019 65
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative 2019 4,818
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive 2019 117
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive 2019 65
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative 2019 2,022
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive 2019 8
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 164
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 261
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 425
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 820
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 816
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 193
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 191
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 2,158
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 2,149
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 226
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 224
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 3,380
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2019 3,398
TX_CURR_DSD Age/Sex: 10-14 Female 2019 11
TX_CURR_DSD Age/Sex: 10-14 Male 2019 10
TX_CURR_DSD Age/Sex: 15-19 Female 2019 109
TX_CURR_DSD Age/Sex: 15-19 Male 2019 72
TX_CURR_DSD Age/Sex: 20-24 Female 2019 385
TX_CURR_DSD Age/Sex: 20-24 Male 2019 152
TX_CURR_DSD Age/Sex: 50+ Female 2019 102
TX_CURR_DSD Age/Sex: 50+ Male 2019 214
TX_CURR_DSD Age/Sex: <1-9 2019 139
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2019 5,678
TX_CURR_DSD Sum of age/sex disaggregates 2019 181
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 1,348
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 906
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 828
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 560
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 275
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 167
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 239
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 161
TX_NEW_DSD Breastfeeding status 2019 24
TX_NEW_DSD By Age/Sex: 1-9 2019 19
TX_NEW_DSD By Age/Sex: 10-14 Female 2019 65
TX_NEW_DSD By Age/Sex: 10-14 Male 2019 5
TX_NEW_DSD By Age/Sex: 15-19 Female 2019 21
TX_NEW_DSD By Age/Sex: 15-19 Male 2019 13
TX_NEW_DSD By Age/Sex: 20-24 Female 2019 191
TX_NEW_DSD By Age/Sex: 20-24 Male 2019 120
TX_NEW_DSD By Age/Sex: 50+ Female 2019 49
TX_NEW_DSD By Age/Sex: 50+ Male 2019 67
TX_NEW_DSD By Age/Sex: <1 2019 7
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 2,174
TX_NEW_DSD Pregnancy status 2019 177
TX_NEW_DSD Sum of Age/Sex disaggregates 2019 531
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 427
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 364
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 209
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 115
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 226
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 108
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 85
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 83
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 1,075
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 970
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 41
TX_PVLS_DSD Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 21
TX_PVLS_DSD Denominator: Indication: Routine 2019 2,107
TX_PVLS_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 2,107
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,016
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 751
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 471
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 419
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 30
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 25
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 26
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 22
TX_RET_DSD Denominator by Status: Breastfeeding 2019 25
TX_RET_DSD Denominator by Status: Pregnant 2019 61
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 1,217
TX_RET_DSD Numerator by Status: Breastfeeding 2019 14
TX_RET_DSD Numerator by Status: Pregnant 2019 14
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 1,543
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Female 2019 73
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Male 2019 74
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Female 2019 1,159
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 2019 1,764
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 815
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 1,955
TX_TB_DSD Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 3,071
TX_TB_DSD Number of ART patients who were screened for TB at least once during the reporting period 2019 3,071
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive 2019 307
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive 2019 1,332
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive 2019 614
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive 2019 614
Cross Cutting Budget Categories and Known Amounts Total: $30,000
Food and Nutrition: Policy, Tools, and Service Delivery $30,000